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ABSTRACT 
Nanoparticles speak to one of the appealing choices in the compelling treatment of tumor chemo-treatment. In the present work, 
definition and improvement of a novel Cetuximab (MTX)- stacked biodegradable nanoparticles utilizing poly(D,L-lactide-co-
glycolide) (PLGA) was done. The arranged nanoparticles were assessed for physicochemical properties, for example, molecule 
measure, zeta potential, discharge thinks about, and so forth. Molecule size of upgraded definition was < 200 nm. Our essential 
outcomes exhibit that the created Cetuximab-stacked PLGA nanoparticles discharging the medication for delayed timeframe. 
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INTRODUCTION 
After cardiovascular ailments, malignancy is the biggest 
reason for death around the world 
(http://www.cdc.gov.in). The word malignancy 
originated from a Greek word "karkinos" to depict 
carcinoma tumors by a doctor Hippocrates (460– 370 
B.C) 
1
. Malignancy can be characterized as an 
uncontrolled development of typical cells in a specific 
piece of the body
2-5
.When growth spreads to alternate 
parts of the body through the circulation system or 
lymphatic framework, this is called metastasis. A 
solitary malignant cell encompassed by solid tissue will 
reproduce at a higher rate than alternate cells. Once a 
little tumor mass has shaped, the sound tissue won't have 
the capacity to rival the growth cells for the insufficient 
supply of supplements from the circulatory system. The 
tumor cells will dislodge solid cells until the point that 
the tumor achieves a dispersion constrained maximal 
size. (www.cancer.gov.in). 
The most widely recognized malignancies are 
anticipated to be lung and bronchus disease, bosom 
tumor, prostate growth, colon and rectum growth, 
bladder growth, melanoma of the skin, non-hodgkin 
lymphoma, thyroid disease, kidney and renal pelvis 
growth, endometrial disease, leukemia, and pancreatic 
malignancy. The quantity of new instances of disease 
(tumor frequency) is 454.8 for every 100,000 people for 
each year (in light of 2008-2012 cases) 
(www.nih.gov.in). The quantity of growth passings 
(malignancy mortality) is 171.2 for each 100,000 people 
for every year (in view of 2008-2012 passings). The 
quantity of individuals living past a growth finding 
achieved about 14.5 million out of 2014 and is required 
to ascend to very nearly 19 million by 2024. In 2014, an 
expected 15,780 kids and youths ages 0 to 19 were 
determined to have tumor and 1,960 passed on of the 
infection. National uses for disease mind in the United 
States totaled almost $125 billion out of 2010 and could 
reach $156 billion of every 2020 (www.nih.gov.in). 
Nanoparticles stacked with anticancer operators can 
effectively build sedate focus in malignancy tissues and 
furthermore act at the cell level, improving antitumor 
viability. The principle points of interest of nanoparticles 
incorporates, the amazing tumor focusing on and can 
escape from the vasculature through the cracked 
endothelial tissue that encompasses the tumor and 
afterward aggregate, bringing about improved 
porousness impacts. These medication conveyance 
frameworks enhance bioavailability by improving fluid 
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solvency, expanding protection time in the body and 
focusing on medication to particular area in the body. 
Different medications utilized as a part of a specific sort 
of disease, for example, erlotinib, geftinib, docetaxel and 
so on are utilized as a part of the treatment of lung 
tumor, while, Cetuximab, doxorubicin, paclitaxel and so 
on. are utilized as a part of the treatment of bosom 
cancer.The point of the present work is to define the 
medication stacked polymeric nanoparticles of 
anticancer medication utilizing pharmaceutical trial plan. 
The goal behind the work is to contemplate the impact of 
definition factors on the molecule estimate, sedate 
exemplification and % aggregate medication arrival of 
nanoparticles.
 6-10
 Study the in vitro release character of 
Cetuximab from the prepared nanoparticles. Study the 
stability of prepared nanoparticles for optimized 
formulations Perform biodistribution and 
pharmacokinetic studies in mice for the Tc
99m
 labeled 
Cetuximab and nanoparticle formulations after 
intravenous and oral administration. Carryout tumor 
uptake studies for radio labeled Cetuximab and 
formulations along with biodistribution studies. Gamma 
scintigraphic imaging was proposed to be used for the 
study.                    
MATERIAL AND METHODS 
Materials  
Poly (lactide-co-glycolide), PLGA (Purasorb R 85/15, 
Mol.wt. 10000) was liberally skilled by Purac chemicals, 
The Netherlands. Poly-ε-caprolactone (PCL) (atomic 
weight of 40000) and Pluronic F 68 were bought from 
Sigma-Aldrich Chemicals, (Milwaukee, WI, USA) . 
Cetuximab was blessing from Dabur Research 
Foundation (Sahibabad, U.P. India). Tc-99m was 
naturally eluted from molybdenum, stannous chloride 
dihydrate was bought from Sigma Chemicals. Triple 
refined water was utilized as a part of the readiness of 
nanoparticles. 
Preparation of Nanoparticles 
11-12
                              
In the present investigation nanoparticles of MTX were 
set up by emulsification dissolvable dissipation strategy 
(Xua et al 2005). In a word, polymer and MTX were 
broken up in CH3)2CO under rapid homogenization 
(Polytron Mixer, Kinematica) at 1000 rpm. The 
polymeric arrangement was test sonicated for 2 min and 
gradually added to the watery stage containing surfactant 
arrangement utilizing fast homogenization at 7000 rpm 
for 10 min. coming about O/W emulsion was again test 
sonicated at 40 W adequacies for 5 min in ice water 
shower. The emulsion was kept for mixing on an 
attractive stirrer at 1200 rpm for finish dissipation of 
natural dissolvable. After entire vanishing of the 
dissolvable, the suspension was centrifuged at 20,000 
rpm for 30 min. The pellet at the base was reconstituted 
in an answer containing mannitol as a cryoprotectant. 
The suspension was profound freezed at – 80 °C for 8 h 
and lyophilized with vacuum weight of < 50 mTorr and 
at a temperature of – 40 °C for 48 h. Supernatant was 
investigated with the expectation of complimentary 
medication (unentrapped) utilizing as a part of house 
created RP-HPLC strategy. 
In vitro Drug Release 
Drug release from nano-particles and subsequent 
biodegradation are important for developing the 
successful formulations. The release rate of drug from 
nano-particles depend upon: (i) desorption of the 
surface-bound /adsorbed drug; (ii) diffusion through the 
nano-particle matrix; (iii) diffusion through the 
nanocapsules polymer wall; iv) nanoparticle matrix 
erosion; and (v) combined erosion and diffusion process. 
Thus, diffusion and biodegradation govern the process of 
drug release. Methods to study the in vitro release are: 
(i) side-by-side diffusion cells with artificial or 
biological membranes; (ii) dialysis bag diffusion 
technique; (iii) reverse dialysis sac technique; (iv) ultra-
centrifugation; (v) ultra-filtration; or (vi) centrifugal 
ultra-filtration technique. 
Animal Models Used for In-vivo Studies 
Strain mice (25 to 30 g) were used for biodistribution, 
pharmacokinetic, tumor development and tumor uptake 
studies. Pharmacokinetic studies of radio labelled 
preparations were conducted in male New Zealand, 
white rabbits of 2 to 2.5 kg. Animals were kept in cages 
at constant temperature and humidity. Water and feed 
were given ad libitum. The Social Justice and 
Empowerment Committee further approved by IAEC, 
Daksh Institute of Pharmaceutical Sciences, Chhatarpur, 
Madhya Pradesh (Ref. No. CPCSEA/2018/12-18) for all 
the animal experiments for the purpose of control and 
supervision of experimental animals, New Delhi, India. 
Biodistribution and Pharmacokinetic Study in 
Healthy Mice 
a) Intravenous Administration (i. v.): 
Tc
99
m labelled Cetuximab and formulations: containing 
around 200 µ Ci of radioactivity was injected into the 
tail vein of healthy mice. For each preparation injected, 
three mice were used per time point. The mice were 
sacrificed at 0.5, 1, 2, 4 and 24 h post administration. 
Before sacrificing mice, at specific time points, mice 
were anaesthetized with excess amount chloroform and 
blood samples were collected by cardiac puncture and 
placed in pre weighed plastic tubes. Various organs like, 
the heart, liver, lungs, muscle, bone (femur), kidneys, 
spleen, gastrointestinal tract (GIT) and brain were then 
isolated. In the case of GIT, the whole tract was excised 
and separated into stomach, small intestine and large 
intestine. All the organs/tissues collected were 
thoroughly rinsed with saline, placed in pre-weighed 
plastic tubes and weighed. The radioactivity was 
determined in a well type gamma scintillation counter 
along with three aliquots of the diluted standard 
representing 100% of the injected radioactivity. Mean of 
this radioactivity was used to obtain the total injected 
radioactivity into the animal. The radioactivity present in 
organs/tissues was interpreted as percentage of the 
injected radioactivity per gram of organ/tissue (% A/g). 
Pharmacokinetic parameters were calculated for the 
blood samples collected in the study. 
 
 
Kaushik et al                                                                                                  Journal of Drug Delivery & Therapeutics. 2018; 8(5-s):184-188           
ISSN: 2250-1177                                                                             [186]                                                                             CODEN (USA): JDDTAO 
b) Oral Administration: 
Tc
99m
 labeled Cetuximab, ETNP/F68/17, 
ETNP/PCL/F68/03, ETNP3/F68 and NP/F68/17 (100 µ 
l) containing around 200 µ Ci of radioactivity were 
administered orally. All other conditions and procedures 
were kept same as mentioned in i. v. administration. The 
radioactivity present in all organs/tissues was determined 
using gamma scintillation counter along with the diluted 
standard representing 100% of the administered 
radioactivity. Mean of this radioactivity was used to 
obtain the total administered radioactivity into the 
animal. The radioactivity present in organs/tissues was 
interpreted as % A/g.  
Lymphoma Tumor Bearing Mice 
a) Tumor Implantation and Development:  
The Dalton’s Lymphoma solid tumor (DLS) cells were 
maintained in the peritoneum of Balb/C mice in the 
ascites form by serial weekly passages. Exponentially 
growing cells were harvested and tumor cells of 5 x 106 
per mouse were injected subcutaneously in the thigh of 
right hind leg of the Strain A mice. After 8 to 10 days a 
palpable tumor in the volume range of 1.0 ± 0.1 cm 3 
was observed and used for further studies. 
b) Biodistribution, Pharmacokinetic and Tumor 
Uptake Study:  
Tc
99m
 labeled Cetuximab (100 µ l) containing around 
200 µ Ci of radioactivity were injected into the tail vein 
of tumor bearing mice. For each injected preparation 
three mice were used per time point. The mice were 
sacrificed 1, 4, and 24 h post injection. Before 
sacrificing those mice, at specified time points, mice 
were anaesthetized with excess amount chloroform and 
blood samples were obtained by cardiac puncture and 
placed in pre-weighed plastic tubes. The heart, liver, 
lungs, muscle, bone (femur), kidneys, spleen, and brain 
were isolated.Along with these organs, tumor was 
excised from the right hind leg. As a control; muscle 
from the right hind leg of a healthy animal, which was 
administered with the same preparation, was used. All 
the organs/tissues collected were thoroughly rinsed with 
saline, placed in pre-weighed plastic tubes and weighed. 
The radioactivity was determined as mentioned above. 
Pharmacokinetic Study in Rabbits 
a) Intravenous Administration: 
Tc
99m
 labeled Cetuximab, ETNP/F68/17, 
ETNP/PCL/F68/03 and NP/F68/17 (250 µ l) containing 
around 6 mCi of radioactivity were injected into the 
marginal ear vein of rabbits. Study was conducted on 
grouping three rabbits per preparation. At specific time 
points, 5, 10, 15, 30 min, 1, 2, 3, 4, 6 and 24 h, blood 
samples were collected from the marginal vein of the ear 
and placed in pre weighed plastic tubes and weighed. 
Radioactivity was checked using gamma counter. Along 
with the blood samples, standard solution, which was 
injected, also checked for radioactivity as it gives total 
injected radioactivity and it was taken as 100%. The 
radioactivity present in blood samples was interpreted as 
percentage of the injected radioactivity per gram of 
blood (% A/g).  
b) Oral Administration:  
Tc
99m
 labeled Cetuximab, ETNP/F68/17 and NP/F68/17 
(500 µ l) containing around 6 mCi of radioactivity were 
administered orally for pharmacokinetic studies. Blood 
samples were collected after 0.5, 1, 2, 3, 4, 6 and 24 h 
post administration of preparations. All other conditions 
and procedures were kept same as mentioned in i.v. 
administration. The radioactivity present in blood was 
determined as above and represented as % A/g. 
Gamma Scintigraphic Imaging:  
For gamma scintigraphic study of Tc99m labeled 
Cetuximab and ETNP/F68/17, 100 µl of preparations 
containing 200 µ Ci of radioactivity was injected 
through the tail vein of the tumor bearing and healthy 
mice. Healthy mice were kept as control. At 4 and 24 h 
of post injection, mice were fixed on animal fixing tray 
board and imaging was performed with Single Photon 
Emission Computed Topography gamma camera. 
Gamma imaging was also done for rabbits after 
administering Tc99m labeled Cetuximab and 
ETNP/F68/17 preparations containing 6 mCi of 
radioactivity through the marginal ear vein of rabbits.  
RESULTS AND DISCUSSION 
Animal Models Used for In vivo Studies 
Strain mice (25 to 30 g) were used for biodistribution, 
pharmacokinetic, tumor development and tumor uptake 
studies. Pharmacokinetic studies of radio labeled 
preparations were conducted in male New Zealand, 
white rabbits of 2 to 2.5 kg. Animals were kept in cages 
at constant temperature and humidity. Water and feed 
were given ad libitum. 
Biodistribution, tumor development, tumor uptake and 
pharmacokinetic studies were carried out at Institute of 
Nuclear Medicine and Allied Sciences (INMAS), New 
Delhi after the prior approval (Sanction number: INM-
302) and in accordance with the rules and regulations of 
the Animal Ethics Committee of INMAS, New Delhi. 
The Social Justice and Empowerment Committee further 
approved all the animal experiments for the purpose of 
control and supervision of experimental animals, New 
Delhi, India. 
Bio-distribution and Pharmacokinetic Study in 
Healthy Mice 
a) Intravenous Administration (i.v.) 
Tc
99
m labeled Cetuximab and formulations: 
ETNP/F68/17, ETNP/PCL/F68/03, ETNP3/F68 and 
NP/F68/17 (100 µ l) containing around 200 µ Ci of 
radioactivity were injected into the tail vein of healthy 
mice. For each preparation injected, three mice were 
used per time point. The mice were sacrificed at 0.5, 1, 
2, 4 and 24 h post administration. Before sacrificing 
mice, at specific time points, mice were anaesthetized 
with excess amount chloroform and blood samples were 
collected by cardiac puncture and placed in pre weighed 
plastic tubes. Various organs like, the heart, liver, lungs, 
muscle, bone (femur), kidneys, spleen, gastrointestinal 
tract (GIT) and brain were then isolated. In the case of 
GIT, the whole tract was excised and separated into 
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stomach, small intestine and large intestine. All the 
organs/tissues collected were thoroughly rinsed with 
saline, placed in pre-weighed plastic tubes and weighed. 
The radioactivity was determined in a well type gamma 
scintillation counter along with three aliquots of the 
diluted standard representing 100% of the injected 
radioactivity. Mean of this radioactivity was used to 
obtain the total injected radioactivity into the animal. 
The radioactivity present in organs/tissues was 
interpreted as percentage of the injected radioactivity per 
gram of organ/tissue (% A/g). Pharmacokinetic 
parameters were calculated for the blood samples 
collected in the study. 
b) Oral Administration 
Tc
99
m labeled Cetuximab, ETNP/F68/17, 
ETNP/PCL/F68/03, ETNP3/F68 and NP/F68/17 (100 µ 
l) containing around 200 µ Ci of radioactivity were 
administered orally. All other conditions and procedures 
were kept same as mentioned in i.v. administration. The 
radioactivity present in all organs/tissues was determined 
using gamma scintillation counter along with the diluted 
standard representing 100% of the administered 
radioactivity. Mean of this radioactivity was used to 
obtain the total administered radioactivity into the 
animal. The radioactivity present in organs/tissues was 
interpreted as % A/g. 
Data Analysis 
Results of the in vivo biodistribution studies were 
statistically evaluated by Student’s t-test with P<0.05 as 
the minimal level of significance. Study was done in 
between free Cetuximab and Cetuximab loaded 
formulations. Pharmacokinetic parameters were assessed 
using non-compartmental technique with the software 
program WinNonlin (version 2.1). The mean %A/g and 
time data was fitted to the model i. v. bolus for i.v. 
administration and extravascular for oral administration. 
Pharmacokinetic parameters like Area under the curve 
(AUC), Mean residence time (MRT), Clearance (Cl), 
t1/2, Tmax, Cmax were calculated using this software. 
 
Table 1: Tissue distribution kinetics of Tc
99m
labeled Cetuximab in healthy mice - after i.v.
 
Time (h) % A/g ± SD 
0.5 1.0 2.0 4.0 24.0 
Stomach 0.021 ± 0.003 0.057 ± 0.008 0.047 ± 0.015 0.078 ± 0.025 0.038 ± 0.016 
Small 
Intestine 
0.759 ± 0.094 1.169 ± 0.307 1.736 ± 0.091 2.143 ± 0.055 0.637 ± 0.131 
Large 
Intestine 
0.237 ± 0.052 0.607 ± 0.092 0.394 ± 0.005 0.246 ± 0.074 0.076 ± 0.012 
 
Table 2: Tissue distribution kinetics of Tc
99m
 labeled nanoparticle formulation (ETNP/F68/17) in healthy mice 
after i.v. administration. 
Time (h) % A/g ± SD 
0.5 1.0 2.0 4.0 24.0 
Stomach 0.689 ± 0.063 0.870 ± 0.066 0.554 ± 0.104 0.403 ± 0.099 0.276 ± 0.101 
Small 
Intestine 
0.469 ± 0.021 0.540 ± 0.213 0.607 ± 0.254 0.962 ± 0.276 0.546 ± 0.327 
Large 
Intestine 
0.471 ± 0.074 0.860 ± 0.332 0.897 ± 0.143 0.587 ± 0.128 0.403 ± 0.07 
Each value is the mean of 3 independent determinations 
 
Figure 1: Gamma Scintigraphic image of DLS tumor 
induced and normal mice 24 h after i.v. administration 
CONCLUSION 
Biodistribution studies of radiolabeled Cetuximab and 
Cetuximab loaded nanoparticles in healthy mice after 
intravenous and oral administration produced different 
distribution profile compared with free drug. Higher 
concentrations of radio labeled Cetuximab loaded 
nanoparticles were observed in blood with increased 
residence time. There was preferential uptake by 
reticuloendothelial system with maximum amount of 
radioactivity observed in liver with lower clearance. 
Nanoparticles prepared with PLGA 85/15, PCL and their 
combination, were distributed more into liver, blood, 
lungs, bone and brain after i.v. and oral administration 
which might be useful in treatment of malignancies in 
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the respective organs. Lower distribution of 
nanoparticles to heart, kidneys could reduce the side 
effects and toxicity. Higher uptake of nanoparticles by 
gut wall of GI tract after oral administration indicates 
potential use of nanoparticles in treatment of GI tract 
malignancies. sites or organs with extended release of 
Cetuximab in the site. These systems can potentially 
avoid problems associated with conventional 
formulations of Cetuximab and demonstrated the 
promising potential of the Cetuximab loaded 
nanoparticles to improve the therapeutic efficacy of 
Cetuximab and reduce drug associated toxicity.However, 
further work is required to be done to enhance the drug 
loading in nanoparticles by varying different parameters 
or change of polymer. Also in vivo therapeutic efficacy 
need to be done in cancer induced animals. On the basis 
of animal studies, clinical trial may be made in human 
volunteers to study the effectiveness and specificity.
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